These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27249730)

  • 21. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the fallopian tube in the origin of ovarian cancer.
    Erickson BK; Conner MG; Landen CN
    Am J Obstet Gynecol; 2013 Nov; 209(5):409-14. PubMed ID: 23583217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
    Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
    Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clear cell carcinoma of the ovary: a review of the literature.
    del Carmen MG; Birrer M; Schorge JO
    Gynecol Oncol; 2012 Sep; 126(3):481-90. PubMed ID: 22525820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into ovarian cancer pathology.
    Prat J
    Ann Oncol; 2012 Sep; 23 Suppl 10():x111-7. PubMed ID: 22987944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coming into focus: the nonovarian origins of ovarian cancer.
    Dubeau L; Drapkin R
    Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii28-viii35. PubMed ID: 24131966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
    Nezhat FR; Apostol R; Nezhat C; Pejovic T
    Am J Obstet Gynecol; 2015 Sep; 213(3):262-7. PubMed ID: 25818671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
    Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.
    Groen RS; Gershenson DM; Fader AN
    Gynecol Oncol; 2015 Feb; 136(2):373-83. PubMed ID: 25481800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Epithelial ovarian cancer - a change of paradigm].
    Heinzelmann-Schwarz V
    Ther Umsch; 2011 Oct; 68(10):565-72. PubMed ID: 21968896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classification of ovarian carcinomas based on pathology and molecular genetics.
    D'Angelo E; Prat J
    Clin Transl Oncol; 2010 Dec; 12(12):783-7. PubMed ID: 21156408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
    Oswald AJ; Gourley C
    Curr Opin Oncol; 2015 Sep; 27(5):412-9. PubMed ID: 26241347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The origin of endometriosis-associated ovarian cancer from uterine neoplastic lesions.
    Garavaglia E; Sigismondi C; Ferrari S; Candiani M
    Med Hypotheses; 2018 Jan; 110():80-82. PubMed ID: 29317075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical prevention strategies in ovarian cancer.
    Mallen A; Soong TR; Townsend MK; Wenham RM; Crum CP; Tworoger SS
    Gynecol Oncol; 2018 Oct; 151(1):166-175. PubMed ID: 30087058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Pathology of Ovarian Epithelial Neoplasms: Predictive, Prognostic, and Emerging Biomarkers.
    Ordulu Z; Watkins J; Ritterhouse LL
    Clin Lab Med; 2024 Jun; 44(2):199-219. PubMed ID: 38821641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?
    Gupta M; Babic A; Beck AH; Terry K
    Hum Pathol; 2016 Aug; 54():82-91. PubMed ID: 27068525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.